Emil M deGoma
Overview
Explore the profile of Emil M deGoma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ajufo E, deGoma E, Raper A, Yu K, Cuchel M, Rader D
Genet Med
. 2021 May;
23(9):1697-1704.
PMID: 34040191
Purpose: Family-based cascade screening from index probands is considered an effective way of identifying undiagnosed individuals with familial hypercholesterolemia (FH). The role of genetic testing of the proband in the...
2.
Haase V, Chertow G, Block G, Pergola P, deGoma E, Khawaja Z, et al.
Nephrol Dial Transplant
. 2018 Apr;
34(1):90-99.
PMID: 29672740
Background: Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain dioxygenases, is an oral investigational agent in development for the treatment of anemia secondary to chronic kidney disease. Methods: In this...
3.
Martin E, Smith M, Maroni B, Zuraw Q, deGoma E
Am J Nephrol
. 2017 Mar;
45(5):380-388.
PMID: 28343225
Background: Therapeutic options for the treatment of anemia secondary to chronic kidney disease (CKD) remain limited. Vadadustat (AKB-6548) is an oral hypoxia-inducible factor prolyl-hydroxylase domain (HIF-PHD) inhibitor that is being...
4.
Millar J, Lassman M, Thomas T, Ramakrishnan R, Jumes P, Dunbar R, et al.
J Lipid Res
. 2017 Mar;
58(6):1214-1220.
PMID: 28314859
Cholesteryl ester transfer protein (CETP) mediates the transfer of HDL cholesteryl esters for triglyceride (TG) in VLDL/LDL. CETP inhibition, with anacetrapib, increases HDL-cholesterol, reduces LDL-cholesterol, and lowers TG levels. This...
5.
Ahmad Z, Andersen R, Andersen L, OBrien E, Kindt I, Shrader P, et al.
J Clin Lipidol
. 2016 Sep;
10(5):1223-9.
PMID: 27678440
Background: In the US familial hypercholesterolemia (FH), patients are underidentified, despite an estimated prevalence of 1:200 to 1:500. Criteria to identify FH patients include Simon Broome, Dutch Lipid Clinic Network...
6.
Millar J, Reyes-Soffer G, Jumes P, Dunbar R, deGoma E, Baer A, et al.
J Clin Invest
. 2016 Apr;
126(4):1603-4.
PMID: 27035815
No abstract available.
7.
deGoma E, Ahmad Z, OBrien E, Kindt I, Shrader P, Newman C, et al.
Circ Cardiovasc Genet
. 2016 Mar;
9(3):240-9.
PMID: 27013694
Background: Cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the United States remain poorly described. In 2013, the FH Foundation launched the Cascade Screening for...
8.
Reyes-Soffer G, Millar J, Ngai C, Jumes P, Coromilas E, Asztalos B, et al.
Arterioscler Thromb Vasc Biol
. 2016 Mar;
36(5):994-1002.
PMID: 26966279
Objective: Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. The mechanisms responsible for...
9.
Nguyen V, deGoma E, Hossain E, Jacoby D
J Clin Lipidol
. 2015 Jun;
9(3):357-9.
PMID: 26073394
Background: In November 2013, the American College of Cardiology and the American Heart Association released new cholesterol guidelines. Implications of these new guidelines for statin prescription remain uncertain, particularly in...
10.
Millar J, Reyes-Soffer G, Jumes P, Dunbar R, deGoma E, Baer A, et al.
J Clin Invest
. 2015 May;
125(6):2510-22.
PMID: 25961461
Background: Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy...